Eric Wooltorton
Abstract
Open-access reader
Reason for posting: Phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra), are drugs used to treat erectile dysfunction that have long been recognized to cause temporary, minor visual changes in less than 10% of users.[1][1] However
OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Reason for posting: Phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra), are drugs used to treat erectile dysfunction that have long been recognized to cause temporary, minor visual changes in less than 10% of users.[1][1] However
Key concepts: Vardenafil, Tadalafil, Erectile dysfunction, Sildenafil, cGMP-specific phosphodiesterase type 5, Medicine, Pharmacology, Internal medicine